Transcend Therapeutics
New York, United States· Est. 2021
Develops novel neuropsychiatric therapeutics targeting the serotonin 2A receptor for conditions like PTSD and depression.
Private Company
Total funding raised: $40M
About
Develops novel neuropsychiatric therapeutics targeting the serotonin 2A receptor for conditions like PTSD and depression.
Psychedelics
Funding History
1Total raised:$40M
Series A$40MJun 15, 2022